Recent Analysts’ Ratings Changes for Natera (NTRA)

Natera (NASDAQ: NTRA) has recently received a number of price target changes and ratings updates:

• 10/27/2026 – Natera had its price target raised by BTIG Research from $320.00 to $430.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Natera is now covered by Roth Capital. They set a “buy” rating and a $475.00 price target on the stock.
• 10/22/2026 – Natera is now covered by Roth Capital. They set a “buy” rating and a $475.00 price target on the stock.
• 10/19/2026 – Natera had its price target raised by Canaccord Genuity Group from $375.00 to $500.00. They now have a “buy” rating on the stock.
• 10/16/2026 – Natera was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/15/2026 – Natera had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/14/2026 – Natera had its price target raised by JPMorgan Chase & Co. from $360.00 to $460.00. They now have an “overweight” rating on the stock.
• 10/13/2026 – Natera had its price target raised by TD Cowen from $340.00 to $480.00. They now have a “buy” rating on the stock.
• 10/12/2026 – Natera had its price target raised by Morgan Stanley from $355.00 to $435.00. They now have an “overweight” rating on the stock.
• 10/7/2026 – Natera had its price target raised by Barclays from $340.00 to $475.00. They now have an “overweight” rating on the stock.
• 10/6/2026 – Natera had its price target raised by Citigroup from $365.00 to $480.00. They now have a “buy” rating on the stock.
• 10/1/2026 – Natera had its price target raised by Guggenheim from $360.00 to $475.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Natera had its price target raised by Royal Bank Of Canada from $350.00 to $460.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Natera had its price target raised by UBS Group from $290.00 to $435.00. They now have a “buy” rating on the stock.
• 9/8/2026 – Natera is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $385.00 price target on the stock.
• 9/8/2026 – Natera was upgraded by Royal Bank Of Canada from “outperform” to “buy”.
• 9/8/2026 – Natera is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $385.00 price target on the stock.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $414.22, for a total transaction of $1,242,660.00. Following the completion of the sale, the insider directly owned 106,914 shares of the company’s stock, valued at approximately $44,285,917.08. This represents a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Chapman sold 1,273 shares of Natera stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $413.31, for a total transaction of $526,143.63. Following the completion of the transaction, the chief executive officer directly owned 96,926 shares in the company, valued at approximately $40,060,485.06. This trade represents a 1.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 38,224 shares of company stock valued at $12,347,229. 5.05% of the stock is currently owned by company insiders.

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.